Lakefront Biotherapeutics (LKFT) FCF Margin (2014 - 2026)
Lakefront Biotherapeutics (LKFT) reported FCF Margin of 1457.94% for Q1 2026, down 140740.0% year-over-year from N/an in Q1 2025, and down 25358.8% quarter-over-quarter from 5.73% in Q4 2025.
Lakefront Biotherapeutics (LKFT) FCF Margin (2014 - 2026) Analysis & Trends
Lakefront Biotherapeutics (LKFT) has 13 years of FCF Margin data on file, last reported at 1457.94% in Q1 2026.
- FCF Margin for Q1 2026 came in at 1457.94%, down 140740.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 13.4% (up 935.0% YoY), and the FY2025 annual result was 24.38%, up 9779.0% from the prior year.
- FCF Margin declined to 1457.94% in Q1 2026 per LKFT's latest filing, from 5.73% in the prior quarter.
- Over five years, FCF Margin peaked at 134.43% in Q4 2022 and troughed at 1457.94% in Q1 2026.
- A 5-year average of 144.24% and a median of 13.36% in 2023 frame the typical range for FCF Margin.
- The sharpest annual moves came in 2025 and 2026: FCF Margin surged 15924 bps in 2025, then tumbled 140740 bps in 2026.
- A 5-year view of FCF Margin shows it stood at 134.43% in 2022, then plunged by 110 bps to 13.36% in 2023, then slumped by 460 bps to 74.81% in 2024, then surged by 92 bps to 5.73% in 2025, then tumbled by 25359 bps to 1457.94% in 2026.
- Business Quant data shows LKFT's FCF Margin at 1457.94% in Q1 2026, 5.73% in Q4 2025, and 4.01% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | - |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | - |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | - |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | -3.98% |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | - |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | - |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | 43.35% |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | - |
| 10 | Lakefront Biotherapeutics | 9.64 Bn | 9.64 Bn | 1.97 Mn | -1,457.94% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1,457.94% |
| Dec 31, 2025 | -5.73% |
| Sep 30, 2025 | 4.01% |
| Jun 30, 2025 | 6.36% |
| Mar 31, 2025 | -50.54% |
| Dec 31, 2024 | -74.81% |
| Sep 30, 2024 | 2.60% |
| Jun 30, 2024 | -13.21% |
| Mar 31, 2024 | -209.78% |
| Dec 31, 2023 | -13.36% |
| Mar 31, 2023 | -158.48% |
| Dec 31, 2022 | 134.43% |
| Mar 31, 2022 | -38.72% |
| Jun 30, 2021 | -50.79% |
| Mar 31, 2021 | -98.97% |
| Jun 30, 2020 | -136.35% |
| Mar 31, 2020 | -65.00% |
| Dec 31, 2019 | -18.79% |
| Sep 30, 2019 | 463.25% |
| Jun 30, 2019 | -117.53% |